The Immortalized Cell Line Market is expected to reach USD 2601.83 Million by 2030 at 4.90% CAGR during the forecast period 2022-2030 Immortalized cell lines are either tumorous cells that do not stop dividing or cells that have been artificially manipulated to proliferate indefinitely and can, thus, be cultured over several generations. These cell lines are expected to grow due to the rise in vaccine production and innovative technologies.
Besides, the ability of cell line culture to provide more physiologically relevant information and more accurate data in-vitro tests has led cell line culture systems to become acceptable in comparison to media culture.
The increasing application in biotech and pharmaceutical companies and hospitals, a growing number of patients in need of organ transplantation, and the rise in the patient population affected by cancer are the major drivers propelling market growth. However, the high cost of equipment and developing a stable strain of cell line and maintaining and preventing it from contamination may hinder the growth of the market.
The increasing demand for organ donation due to scarcity in the availability of organs is driving the need for artificially created biological cells. For instance, according to the US Department of Health & Human Services Organ Procurement and Transplantation Network (OPTN), as of November 2016, 121,678 patients were waiting for a life-saving organ transplant. This rising demand for an organ transplant is expected to drive the growth of the market during the forecast period. Additionally, increasing application in biotech and pharmaceutical companies and hospitals and rise in the patient population affected by cancer are likely to support market growth. On the other hand, the high cost of equipment and developing a stable strain of cell line and maintaining and preventing it from contamination is anticipated to hamper the market growth.
Immortalized Cell Line Market Size, by End User, 2017 (USD Million)
Source: MRFR Analysis
The immortalized cell line market has been segmented into method, application, and end user.
Based on the method, the global market has been segmented into virus induction, hTERT expression, inactivation of tumor suppression genes, and others. The virus induction segment is further divided into EBV genes, SV40 T antigen, HPV-16 E6/6 gene, and others. The hTERT expression segment is sub-segmented into P53 and Myc T58A.
The immortalized cell line market, based on application, is segmented into diagnostics, drug discovery, vaccine production, tissue engineering and regenerative medicine, and others.
Based on end user, the global market is segmented into pharmaceutical and biopharmaceutical companies, Contract Research Organizations (CROs), and research laboratories. The pharmaceutical and biopharmaceutical companies segment accounted for a market value of USD 1,323.79 million in 2017.
The prominent players in the immortalized cell line market are Thermo Fisher Scientific (US), ATCC (American Type Culture Collection Inc.) (US), Valneva (France), Sartorius AG (Germany), Lonza Group, AG (Switzerland), Merck KGaA (Germany), Selexis SA (Switzerland), WuXi App Tec (China), European Collection of Authenticated Cell Cultures (ECACC) (Europe), and Corning Incorporated (US)
Some of the key strategies followed by the players operating in the immortalized cell line market are innovation, product development, acquisition, and expansion.
Immortalized Cell Line Market Share, by Region, 2017 (%)
Source: MRFR Analysis
The immortalized cell line market, based on region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is estimated to dominate the immortalized cell line market during the forecast period. This is attributed to an increase in the occurrence of cancer, the presence of well-established pharmaceutical and biotechnology industry, increasing awareness of immortalized cell lines, and strong research funding.
The European market for immortalized cell line is expected to be the second-largest during the forecast period. Increasing government support, well-developed technology, and rising cases of cancer are expected to boost the growth of the market in this region.
Asia-Pacific is estimated to be the fastest-growing market due to the increasing expenditure on healthcare by government and private sector companies. Moreover, the growing awareness about healthcare and large untapped patient population have led to the increased focus of key players on expansion in this region. Furthermore, the region accounted for a market share of 17.8% in 2017.
The immortalized cell line market in the Middle East & Africa is expected to hold the least market share.
- In April 2018, Lonza Group, AG announced the opening of the world’s largest dedicated cell-and-gene-therapy manufacturing facility in Pearland, Greater Houston, TX (US). The manufacturing site was built in anticipation of the rising demand from developers of cell and gene therapies.
- In August 2017, Thermo Fisher Scientific acquired Patheon for 7.2 USD million. Patheon’s CDMO services are likely to complement Thermo Fisher Scientific’s life sciences technologies designed to support research, clinical trials, and production.
Immortalized Cell Line Market, by Method
- Virus Induction
- EBV genes
- SV40 T antigen
- HPV-16 E6/6 gene
- HTERT Expression
- Inactivation of Tumour Suppression Genes
Immortalized Cell Line Market, by Application
- Drug Discovery
- Vaccine Production
- Tissue Engineering and Regenerative Medicines
Immortalized Cell Line Market, by End User
- Pharmaceutical and Biopharmaceutical Companies
- Contract Research Organizations
- Research Laboratories
Immortalized Cell Line Market, by Region
- North America
- South America
- Western Europe
- Rest of Western Europe
- Eastern Europe
- South Korea
- Rest of Asia-Pacific
Research and development (R&D) companies
Government research institutes
Academic institutes and universities